Marc Davies

Marc has worked on CAR T-cell therapies for almost 20 years, with his research focussing specifically on the design, development and clinical translation of novel treatments for solid tumours. He joined Leucid Bio in 2021 as VP, R&D to manage their burgeoning pipeline and flagship asset, LEU011, which is currently in a first-in-human Phase I/II clinical trial for solid tumours.